K. DeSantes

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

B. Hasegawa, K. Matthay, V. Weinberg, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores.

S. Anderson, O. Press, F. Geissler, 1990, Cancer research.

Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.

B. Hasegawa, K. Matthay, R. Seeger, 1998, Medical and pediatric oncology.

Genotypes of NK cell KIR Receptors , Their Ligands , and Fc γ Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy : A Children ’ s Oncology Group Report #

J. Kolesar, R. Reisfeld, S. Seo, 2010 .

Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial.

S. Groshen, J. Maris, K. Matthay, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.